Zymergen Stock

zymergen.com/Healthcare / BioTech & PharmaFounded: 2013Funding to Date: $920.06MM

Zymergen is a developer of unique materials and products for a range of industries – from agriculture to electronics, consumer care to pharmaceuticals, and more.

Register To Buy and Sell Shares

For more details on financing and valuation for Zymergen, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access Zymergen’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Zymergen.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.


Management Team

Zach Serber
Chief Science Officer and Founder
Jack Gold
Chief Marketing Officer
Mina Kim
Chief Legal Officer
Jed Dean
VP of Operations and Engineering
Aaron Kimball
Chief Technical Officer
Richard Pieters
President, Products
Joshua Hoffman
Chief Executive Officer
Judy Gilbert
Chief People Officer
Enakshi Singh
VP of Finance

Board Members

Steven Chu
Stanford University
Deep Nishar
Soft Group International
Rohit Sharma
True Ventures
Jay T. Flatley
Illumina Inc
Matt Ocko
Joshua Hoffman
Jed Dean
Sandra E. Peterson
Clayton, Dubilier & Rice, LLC

News Highlights

Ginkgo Buys Embattled Biotech Firm Zymergen For $300 Million
Ginkgo Bioworks acquired biotechnology firm Zymergen, the synthetic biology companies announced Monday morning, marking the final act in Zymergen’s dramatic and brisk fall from grace.
ZYMERGEN DEADLINE ALERT: Faruqi & Faruqi LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Zymergen To Contact Him Directly To Discuss Their Options
NEW YORK, Oct. 03, 2021 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against...
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds Zymergen (ZY) Investors of Securities Class Action, Encourages Investors with Losses to Contact Firm’s Attorneys Now
SAN FRANCISCO, Sept. 18, 2021 (GLOBE NEWSWIRE) -- Hagens Berman urges Zymergen Inc. (NASDAQ: ZY) investors with significant losses to submit your losses...
Updated on: May 21, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.